Allosteric agonist modulators

Journal of Receptors and Signal Transduction

Volumn 27, Issue 4, 2007, Pages 247-259

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Agonists; Allosteric modulators; Drug screening

Indexed keywords

ALLOSTERIC AGONIST MODULATOR; LIGAND; UNCLASSIFIED DRUG;

AGONIST; ALLOSTERISM; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; HIGH THROUGHPUT SCREENING; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; KINETICS; LIGANDS; MODELS, CHEMICAL; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 34548853458     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890701509000     Document Type: Article

References (25)

1. Schwartz TW, Holst B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Receptors Signal Trans 2006, 26(1-2), 107-128.
2. Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988, 33, 187-194.
3. Black JW, Leff P. Operational models of pharmacological agonist. Proc Roy Soc Lond [Biol] 1983, 220, 141-162.
4. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-414.
5. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000, 11, 199-206.
6. Rogers SL, Farlow MR, et al. The Donepezil Study Group. Neurology 1998, 50, 136.
7. Maelicke A. Albuquerque EX. New approach to drug therapy in Alzheimer's dementia. Drug Discovery Today 1996, 1, 53-59.
8. Krause RM, Buisson B, Bertrand S, Corringer P-J, Galzi J-L, Changeux J-P, Bertrand D. Ivermectin: A positive allosteric effector of the 7 neuronal nicotinic acetylcholine receptor Mol Pharmacol 1998, 53, 283-294.
9. May LT, Leach K et al. Allosteric modulation of G protein-coupled receptors Ann Rev Pharmacol Toxicol 2007, 47, 1-51.
10. Rees S, Morrow D, Kenakin T, GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 2002, 8, 261-268.
11. Holst B, Elling CE, Schwartz TW. Metal-ion mediated agonism and agonist enhancement in the melanocortin MC1 and MC4 receptors. J Biol Chem 2002, 277, 47662-47670.
12. Bruns RF, Fergus JH. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990, 38, 939-949.
13. B receptor. J Biol Chem 2004, 279, 29085-29091.
14. Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hostetter Km Froestl W, Bettler B, Kaupmann K. Positive allosteric modulation of native and recombinant gamma-aminobutyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2- dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001, 60, 963-971.
15. Langmead CJ, Victoria AH, et al. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic m1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 2006, 69, 236-246.
16. Langmead CJ, Christopoulos A. Allosteric agonists of 7TM receptors: Expanding the pharmacological toolbox. Trends Pharmacol Sci 2006, 27, 475-481.
17. Sur C, Mallorga PJ, et al. N-Desmethylclozapine, an allosteric agonist at the muscarinic m1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 2003, 100, 13674-13679.
18. Spalding T, Trotter C, Skjaerbaek N, Messier TL, Currier E, Burstein ES, Li D, Hacksell U, Brann MR. Discovery of an ectopic activation site on the muscarinic m1 receptor. Mol Pharmacol 2002, 61, 1297-1302.
19. Elies R, Fu LX, Eftekhari P, Wallukat G, Schulze W, Granier C, Hjalmarson A, Hoebke J. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the m2 acetylcholine receptor. Eur J Biochem 1998, 251, 659-666.
20. Jakubik J, Bacakova L, Esam VL, El-Fakahany EE, Tucek S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA 1996, 93, 8705-8709.
21. 2+ current by a monoclonal antibody against the m2 Ach receptor. Am J Physiol Cell Physiol 2001, 281, C1251-C1258.
22. Holst B, Brandt E, Bach A, Heding A, Schwartz TW. Nonpeptide and peptide growth hormone secretagogues act as both ghrelin receptors and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 2005, 19, 2400-2411.
23. Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, Cohen-Gonsaud M, Acher F, Prezeau L, Pin JP. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci USA 2004, 101, 378-383.
24. Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S, Stoehr N, Mombereau C, Kuhn R, McAllister KH, van der Patten H, Cryan JF, Flor PJ. A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci USA 2005, 102, 18712-18717.
25. Sachpatzidis A, Benton BK, et al. Identification of allosteric peptide agonists of CXCR4R. J Biol Chem 2003, 278, 896-907.